Join us in an engaging webinar as Adrian Simpson, from HDT Bio, delves into the intriguing science behind their novel emulsion platform, known as LION. Discover how this cutting-edge platform enables ...
SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid ...
SEATTLE, Aug. 7, 2024 /PRNewswire/ -- HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, today announced the publication demonstrating the potential for ...
LION™-formulated repRNA vaccination exhibited a significant safety profile, along with enhanced efficacy and biodistribution response when compared to lipid nanoparticle (LNP)-formulated repRNA ...
SEATTLE--(BUSINESS WIRE)--HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today publication in eLife of results of preclinical research that demonstrate ...
SEATTLE, May 21, 2026 /PRNewswire/ -- HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) ...
HDT Bio's work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company's vaccine platforms combine formulation and ...
STONY BROOK, NY / ACCESSWIRE / April 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results